Arcera Life Sciences Launches Breakthrough Antibiotic in UAE to Combat Antimicrobial Resistance
核心洞察
Arcera Life Sciences (搜索) has launched a breakthrough intravenous antibiotic (搜索) in the UAE that restores efficacy against multidrug-resistant bacteria (搜索), including Extended Spectrum Beta-Lactamase (搜索) (ESBL)-producing pathogens.
The launch addresses antimicrobial resistance (搜索) (AMR), which caused 1.14 million deaths globally in 2021 and is projected to cause 39 million deaths over the next 25 years without urgent intervention.
Arcera has signed a strategic partnership with ISPOR UAE Chapter (搜索) to advance health economics research and support evidence-based healthcare decision-making in the region.
Arcera Life Sciences (搜索), a global life sciences company headquartered in Abu Dhabi, has announced the launch of a breakthrough intravenous antibiotic (搜索) in the UAE designed to combat antimicrobial resistance (搜索) (AMR), one of the world's most pressing public health threats. The launch coincides with the signing of a strategic Memorandum of Understanding with ISPOR UAE Chapter (搜索) during the ISPOR UAE Chapter 2026 Conference in Abu Dhabi.
Addressing a Critical Global Health Crisis
Antimicrobial resistance (搜索) represents a significant threat to modern medicine, with the World Health Organization classifying it as a top global public health concern. In 2021 alone, an estimated 1.14 million deaths were directly attributed to bacterial AMR worldwide. Without urgent intervention, forecasts predict a cumulative 39 million deaths directly linked to bacterial AMR over the next 25 years—equivalent to approximately 3 deaths every minute.
The economic implications are equally staggering. Global economic forecasts by the World Bank indicate that rising AMR could contribute to up to $3.4 trillion in annual global GDP losses by 2030 due to healthcare costs, productivity loss, and economic disruption. In the Eastern Mediterranean Region specifically, there were 380,000 deaths associated with AMR and around 92,800 deaths directly attributable to AMR in 2021.
Innovative Treatment Solution
The newly introduced intravenous antibiotic (搜索) restores efficacy against multidrug-resistant bacteria (搜索), including Extended Spectrum Beta-Lactamase (搜索) (ESBL)-producing pathogens, offering physicians a new treatment option for challenging infections. The innovative therapy aligns with the UAE's national antimicrobial stewardship programs aimed at preserving last-line medical agents.
"Building future-ready healthcare systems requires trusted partnerships and the right policy frameworks to translate science into real-world impact," said Isabel Afonso, Chief Executive Officer of Arcera Life Sciences (搜索). "This partnership with ISPOR UAE Chapter (搜索) reflects our shared commitment to advancing health economics, outcomes research, and health technology assessment in the UAE."
Strategic Partnership for Healthcare Innovation
The strategic MoU with ISPOR UAE Chapter (搜索) establishes a framework for cooperation focused on advancing health economics and outcomes research (HEOR) and health technology assessment (HTA) in the UAE. Through this partnership, both organizations will work together to enhance research capabilities, build national expertise, and support evidence-based decision-making.
Prof. Nadia AL Mazrouei, ISPOR UAE Chapter (搜索) President, commented: "We are pleased to welcome Arcera as a strategic partner in our mission to improve healthcare decision-making. The UAE is a rapidly evolving market for health technology, and by combining ISPOR UAE Chapter's global network and resources with Arcera's regional leadership, we can more effectively address the unique challenges of this landscape and promote excellence in research and policy."
Regional Expansion Plans
Arcera has significantly advanced its efforts to secure regulatory approval and prepare for the antibiotic's launch across the GCC region. The company is also progressing registration plans for South Africa, where regulatory approval is expected in early 2027, reinforcing its commitment to improving patient outcomes and ensuring timely access to life-saving therapies.
Policy Leadership and Future Vision
As part of the conference program, Isabel Afonso participated in a panel discussion titled "Securing the Future: Policies to Strengthen Healthcare for the Next Generation in the Middle East and Africa Region." The session featured distinguished global experts and focused on creating robust policy frameworks that promote innovation while ensuring long-term system sustainability.
The MoU reflects a shared commitment to strengthening healthcare policy, improving patient access to innovative therapies, and supporting the UAE's ambition to become a global leader in healthcare excellence and life sciences. Under the agreement, Arcera and ISPOR UAE Chapter (搜索) will also collaborate to promote capacity building, career development, and mentorship in the healthcare sector.